Notice: This company has been marked as potentially delisted and may not be actively trading. Talaris Therapeutics (TALS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendInsider TradesOwnershipTrends TALS vs. CALT, MESO, STML, NAUT, FULC, ADMA, CRSP, IMVT, DNLI, and IBRXShould you be buying Talaris Therapeutics stock or one of its competitors? The main competitors of Talaris Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Mesoblast (MESO), Stemline Therapeutics (STML), Nautilus Biotechnology (NAUT), Fulcrum Therapeutics (FULC), ADMA Biologics (ADMA), CRISPR Therapeutics (CRSP), Immunovant (IMVT), Denali Therapeutics (DNLI), and ImmunityBio (IBRX). These companies are all part of the "medical" sector. Talaris Therapeutics vs. Calliditas Therapeutics AB (publ) Mesoblast Stemline Therapeutics Nautilus Biotechnology Fulcrum Therapeutics ADMA Biologics CRISPR Therapeutics Immunovant Denali Therapeutics ImmunityBio Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Talaris Therapeutics (NASDAQ:TALS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, community ranking, risk and institutional ownership. Which has more volatility & risk, CALT or TALS? Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Talaris Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Does the MarketBeat Community prefer CALT or TALS? Calliditas Therapeutics AB (publ) received 14 more outperform votes than Talaris Therapeutics when rated by MarketBeat users. Likewise, 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote while only 48.15% of users gave Talaris Therapeutics an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Talaris TherapeuticsOutperform Votes1348.15% Underperform Votes1451.85% Does the media refer more to CALT or TALS? In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Talaris Therapeutics'average media sentiment score. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Talaris Therapeutics Neutral Is CALT or TALS more profitable? Talaris Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Talaris Therapeutics' return on equity of -39.93% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Talaris Therapeutics N/A -39.93%-37.37% Do institutionals and insiders hold more shares of CALT or TALS? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 67.6% of Talaris Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 16.5% of Talaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend CALT or TALS? Calliditas Therapeutics AB (publ) currently has a consensus price target of $39.25, indicating a potential downside of 1.88%. Given Calliditas Therapeutics AB (publ)'s higher possible upside, equities analysts clearly believe Calliditas Therapeutics AB (publ) is more favorable than Talaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Talaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has better earnings and valuation, CALT or TALS? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Talaris Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Talaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Talaris TherapeuticsN/AN/A-$73.89M-$1.79-15.03 SummaryTalaris Therapeutics beats Calliditas Therapeutics AB (publ) on 7 of the 13 factors compared between the two stocks. Ad Porter & CompanyThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Get Talaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TALS vs. The Competition Export to ExcelMetricTalaris TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$3.15B$5.22B$8.51BDividend YieldN/A1.75%5.06%4.17%P/E Ratio-15.036.3392.8912.89Price / SalesN/A321.691,681.9389.91Price / CashN/A144.8633.8331.25Price / Book6.214.004.734.56Net Income-$73.89M-$42.25M$116.42M$224.58M Talaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TALSTalaris TherapeuticsN/A$26.90+2.3%N/A+56.7%$1.15BN/A-15.0384CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180Upcoming EarningsMESOMesoblast2.2727 of 5 stars$8.34-1.7%$11.50+37.9%+223.3%$968.23M$5.90M0.0080STMLStemline TherapeuticsN/A$11.83flatN/A+0.0%$621.21M$43.22M-7.4492NAUTNautilus Biotechnology1.8975 of 5 stars$2.57-1.5%$4.50+75.1%-10.5%$322.69MN/A-4.59130Earnings ReportFULCFulcrum Therapeutics3.5543 of 5 stars$3.26+1.6%$9.33+186.3%-16.2%$200.31M$2.81M-9.31100Positive NewsADMAADMA Biologics2.5891 of 5 stars$19.11-1.3%$15.50-18.9%+423.6%$4.45B$258.21M136.50530Upcoming EarningsCRSPCRISPR Therapeutics2.0629 of 5 stars$50.59-0.3%$75.19+48.6%-0.8%$4.32B$371.21M-15.66473IMVTImmunovant2.8009 of 5 stars$29.42+0.1%$48.10+63.5%-13.4%$4.30BN/A-15.24120DNLIDenali Therapeutics4.3891 of 5 stars$27.21+0.6%$38.90+43.0%+24.6%$3.87B$330.53M-9.55364Gap UpIBRXImmunityBio0.8051 of 5 stars$5.20-1.5%$4.75-8.7%+38.7%$3.68B$620,000.00-5.36590 Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Alternatives Mesoblast Alternatives Stemline Therapeutics Alternatives Nautilus Biotechnology Alternatives Fulcrum Therapeutics Alternatives ADMA Biologics Alternatives CRISPR Therapeutics Alternatives Immunovant Alternatives Denali Therapeutics Alternatives ImmunityBio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TALS) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TALS Stock Alerts